Septerna, Inc. CFO Gil M. Labrucherie Acquires Additional Shares

On February 21st, Gil M. Labrucherie, the Chief Financial Officer of Septerna, Inc. (NASDAQ:SEPN - Get Free Report), made a notable investment by acquiring 5,000 shares of the company's stock. The shares were purchased at an average price of $5.85 each, culminating in a total transaction value of $29,250. Following this acquisition, Labrucherie now directly holds 30,000 shares in Septerna, with a total value of $175,500. This recent purchase marks a significant 20% increase in his ownership stake.

Market Performance of Septerna Stock

On the day of the transaction, shares of Septerna opened at $5.80. Over the past year, the stock has experienced a low of $4.17 and a high of $28.99. Furthermore, the company's 50-day moving average stands at $17.78, indicating significant volatility within the stock's price range.

Recent Institutional Investments in Septerna

Recently, several institutional investors and hedge funds have adjusted their stakes in Septerna. Notable transactions include RA Capital Management L.P.'s new investment worth approximately $160.2 million in the fourth quarter, followed by TRV GP V LLC's investment of around $142.3 million. Additionally, TRV GP VI LLC and Samsara BioCapital LLC made new positions valued at $72.2 million and $63.4 million, respectively, while Driehaus Capital Management LLC also entered with a stake of about $59.3 million.

Analysts and Price Targets for Septerna

Various analysts have recently weighed in on Septerna's stock. On November 19th, JPMorgan Chase & Co. started coverage on Septerna, providing an "overweight" rating with a price target of $38.00. Similarly, TD Cowen issued a "buy" rating. On February 11th, Cantor Fitzgerald reaffirmed an "overweight" rating, setting a price target of $50.00. However, not all analysts are optimistic; Wells Fargo & Company downgraded their rating from "overweight" to "equal weight" and reduced their price target from $43.00 to $14.00.

About Septerna, Inc.

Septerna, Inc. is a clinical-stage biotechnology company focused on pioneering new approaches in G protein-coupled receptor (GPCR) drug discovery using its proprietary Native Complex Platform™. This platform is designed to unlock the potential of GPCR therapies, leading to a diverse pipeline of product candidates targeting diseases in endocrinology, immunology, inflammation, and metabolism.

CFO, Shares, Investment